Skip to main content


BARDA supports development of AI-based handheld ultrasound to triage trauma or lung injuries and disease diagnosis, including COVID-19

BARDA Response

BARDA’s investment will accelerate development of machine-learning (ML) algorithms in ultrasound technology across multiple areas of routine and emergency clinical use.

BARDA and Philips North America are collaborating to expand the capability of the compact Philips Lumify - an app-based hand-held ultrasound system - with predictive machine-learning (ML) algorithms to provide real-time analysis.

BARDA is supporting the point-of-care ultrasound device to achieve 510(k) clearance for lung imaging to enable early and accurate detection and diagnosis of patients with smoke inhalation injury and viral pneumonia, including COVID-19.

Development of this multifunctional system supports three independent needs that BARDA identified in collaboration with partners at the American Burn Association and the American College of Surgeons Committee on Trauma. These efforts will focus on:

1) advanced development of a next generation ultrasound for lung imaging,

2) focused assessment with sonography for trauma (FAST) exams, and

3) detection of compartment syndrome – a painful condition that occurs when pressure within the muscles builds to

dangerous levels.

BARDA aims to transform routine care with medical countermeasure technologies so that they can be used easily in responding to disease outbreaks and mass casualty incidents.

Philips also will develop a novel 3D-ultrasound transducer for use in the ML-based FAST exam (effort #2 above) for rapid, automated diagnostic screening of patients with abdominal trauma. These technical advances will allow faster and better delivery of care as well as expand the trained user base.

In addition, the envisioned ultrasound technology aims to transform the current standard of care in the diagnosis of acute compartment syndromes of the extremities. BARDA will continue to model and evaluate the cost-effectiveness impact, and ensure value generation from these new transformative MCM technologies.

This Advanced Research and Development contract has been awarded by the Burn Program, a component of BARDA’s CBRN Division.


This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About the Company: 
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Philips North America is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Philips North America Headquartered in Cambridge, MA, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics and ultrasound, as well as in consumer health and home care. News about Philips can be found at https://www.usa.philips.com/.

Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov